Vimta Labs Ltd

Vimta Labs Employee Stock Options

Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.

Vimta Labs Credit Rating

CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.

Vimta Labs Price Movement Clarification

Vimta Labs clarified that recent increases in its share volume are due to market factors and not related to any undisclosed company information or developments.

Vimta Labs Adverse Business Impact

Vimta Labs reported a cyber security incident affecting its IT infrastructure. The company confirmed operations remain fully functional with no material impact identified thus far.

Vimta Labs Investor Presentation: Key Takeaways

Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.

Call

Guides 25% growth

Vimta Labs Other Announcement

Vimta Labs Ltd filed its quarterly shareholding pattern disclosure for the period ending June 30, 2026, pursuant to SEBI Regulation 31(1)(b).

Vimta Labs Results Update

Vimta Labs announced Q1 FY27 results with total income of ₹112.90 Crore. The company reported a PAT of ₹21.00 Crore for the quarter.

Value

₹112.9 Cr

Vimta Labs Earnings Call: Key Takeaways

Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.

Vimta Labs Q1 FY27 Results: Net Profit ₹21 Cr, Up 11.1% YoY

Vimta Labs Ltd reported revenue from operations of ₹109.1 Cr (+11.8% YoY) and net profit of ₹21 Cr (+11.1% YoY) for Q1 FY27.

Key figure

Net profit ₹21 Cr · +11.1% YoY

Vimta Labs Board Meeting Date

Vimta Labs scheduled a board meeting on July 20, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.